Alzheimer's Association International Conference 2007
CONFERENCE 2007-06-09 00:00:00-2007-06-12 00:00:00 Washington, DC, U.S.A. 09 June 2007 to 12 June 2007 Alzheimer's Association International Conference 2007 View Conference Website 0
SEARCH RESULTS
331254 RESULTS
Paper Alert: Preclinical Alzheimer’s Stages Predict Progression
RESEARCH NEWS 2013-09-25 Research News Proposed preclinical stages for Alzheimer’s disease work well to predict who is most likely to progress to AD, according to a paper released online by Lancet Neurology on September 4. Researchers led by Stephanie Vos and Pieter Jelle Visser
PAPER Byrne S, Heverin M, Elamin M, Walsh C, Hardiman O
Intermediate repeat expansion length in C9orf72 may be pathological in amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Sep 23; PubMed: 24053774PAPER Dols-Icardo O, García-Redondo A, Rojas-García R, Sánchez-Valle R, Noguera A, Gómez-Tortosa E, Pastor P, Hernández I, Esteban-Pérez J, Suárez-Calvet M, Antón-Aguirre S, Amer G, Ortega-Cubero S, Blesa R, Fortea J, Alcolea D, Capdevila A, Antonell A, Lladó A, Muñoz-Blanco JL, Mora JS, Galán-Dávila L, Rodríguez de Rivera FJ, Lleó A, Clarimón J
Characterization of the repeat expansion size in C9orf72 in amyotrophic lateral sclerosis and frontotemporal dementia.
Hum Mol Genet. 2013 Oct 8; PubMed: 24057670Ayano Kimura
Japan
PAPER Gardai SJ, Mao W, Schüle B, Babcock M, Schoebel S, Lorenzana C, Alexander J, Kim S, Glick H, Hilton K, Fitzgerald JK, Buttini M, Chiou SS, McConlogue L, Anderson JP, Schenk DB, Bard F, Langston JW, Yednock T, Johnston JA
Elevated alpha-synuclein impairs innate immune cell function and provides a potential peripheral biomarker for Parkinson's disease.
PLoS One. 2013;8(8):e71634. PubMed: 24058406PAPER Fagerqvist T, Näsström T, Ihse E, Lindström V, Sahlin C, Fangmark Tucker SM, Kasaryan A, Karlsson M, Nikolajeff F, Schell H, Outeiro TF, Kahle PJ, Lannfelt L, Ingelsson M, Bergström J
Off-pathway α-synuclein oligomers seem to alter α-synuclein turnover in a cell model but lack seeding capability in vivo.
Amyloid. 2013 Dec;20(4):233-44. PubMed: 24053224PAPER Asci R, Vallefuoco F, Andolfo I, Bruno M, De Falco L, Iolascon A
Trasferrin receptor 2 gene regulation by microRNA 221 in SH-SY5Y cells treated with MPP(+) as Parkinson's disease cellular model.
Neurosci Res. 2013 Sep 17; PubMed: 24055409PAPER Kang L, Janowska MK, Moriarty GM, Baum J
Mechanistic Insight into the Relationship between N-Terminal Acetylation of α-Synuclein and Fibril Formation Rates by NMR and Fluorescence.
PLoS One. 2013;8(9):e75018. PubMed: 24058647PAPER Pontes-Neto OM, Auriel E, Greenberg SM
Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy.
Eur Neurol Rev. 2012 Summer;7(2):134-139. PubMed: 24058380PAPER Prestia A, Baglieri A, Pievani M, Bonetti M, Rasser PE, Thompson PM, Marino S, Bramanti P, Frisoni GB
The in vivo topography of cortical changes in healthy aging and prodromal Alzheimer's disease.
Suppl Clin Neurophysiol. 2013;62:67-80. PubMed: 24053032PAPER Vecchio F, Babiloni C, Lizio R, Fallani Fd, Blinowska K, Verrienti G, Frisoni G, Rossini PM
Resting state cortical EEG rhythms in Alzheimer's disease: toward EEG markers for clinical applications: a review.
Suppl Clin Neurophysiol. 2013;62:223-36. PubMed: 24053043PAPER Yener GG, Başar E
Biomarkers in Alzheimer's disease with a special emphasis on event-related oscillatory responses.
Suppl Clin Neurophysiol. 2013;62:237-73. PubMed: 24053044PAPER Li Y, Liu Y, Wang Z, Jiang Y
Clinical trials of amyloid-based immunotherapy for Alzheimer's disease: end of beginning or beginning of end?
Expert Opin Biol Ther. 2013 Nov;13(11):1515-22. PubMed: 24053611PAPER Thouvenot E, Camu W
[Vitamin D and neurology.]
Presse Med. 2013 Oct;42(10):1398-404. PubMed: 24054766Current Filters
No filters selected